Yüklüyor…
B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors
Growing evidence links the aggressiveness of non-Hodgkin’s lymphoma, especially the activated B cell-like type diffuse large B cell lymphomas (ABC-DLBCLs) to Toll-like receptor 9 (TLR9)/MyD88 and STAT3 transcription factor signaling. Here, we describe a dual-function molecule consisting of a clinica...
Asıl Yazarlar: | , , , , , , , , , , , , , |
---|---|
Materyal Türü: | Online Makale Metin |
Dil: | English |
Baskı/Yayın Bilgisi: |
American Society of Gene & Cell Therapy
2018
|
Konular: | |
Online Erişim: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910676/ https://www.ncbi.nlm.nih.gov/pubmed/29433938 http://dx.doi.org/10.1016/j.ymthe.2018.01.007 |